Inactive Instrument

Analyst Reco. Regulus Therapeutics Inc Nasdaq

Equities

Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating	Mar. 19	MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target	Mar. 18	MT
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating	Mar. 13	MT
Canaccord Genuity Raises Regulus Therapeutics' Price Target to $12 From $9, Keeps Buy Rating	23-09-21	MT
HC Wainwright Adjusts Price Target on Regulus Therapeutics to $9 From $20, Maintains Buy Rating	23-04-21	MT
Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target	22-11-08	MT
Wedbush Adjusts Regulus Therapeutics' Price Target to $0.42 From $1 Following Private Equity Placement; Neutral Rating Kept	22-01-21	MT
REGULUS THERAPEUTICS : Cantor Fitzgerald Reinstates Regulus Therapeutics at Overweight with $2 Price Target	21-09-02	MT
REGULUS THERAPEUTICS : Wedbush Halves Regulus Therapeutics' PT to $1 From $2 on RGLD4326 Timeline for Autosomal Dominant Polycystic Kidney Disease; Neutral Rating Kept	21-05-14	MT
REGULUS THERAPEUTICS : HC Wainwright Adjusts Regulus Therapeutics' Price Target to $2 From $1.50, Maintains Buy Rating	21-05-14	MT
REGULUS THERAPEUTICS : Wedbush Adjusts Price Target on Regulus Therapeutics to $2 From $1, Maintains Neutral Rating	21-02-17	MT

No results for this search